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Abstract
We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive
dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention-to-treat analysis with
36 months follow-up. Early cytogenetic and molecular responses were superior in the dasatinib group,
with a tendency that imatinib patients caught up with time. For instance, MR3.0 was reached at 3 months
in 36% vs. 8% (P = 0.02), at 12 months in 81% vs. 46% (P = 0.02) and at 18 months in 73% vs. 65%
(n.s.) of the patients in the two groups. In contrast, MR4.5 was consistently superior in the dasatinib group
at all time points from 6 months onwards, reaching 61% vs. 21% (P < 0.05) at 36 months. Sixty-four vs.
71% of the patients in the dasatinib and imatinib arms, respectively, remained on assigned drug. Dasatinib
dose was frequently reduced, but with maintained excellent effect. One imatinib patient progressed to
blastic phase, but no CML-related deaths occurred. In conclusion, our data compare favourably with those
of the dasatinib registration study, DASISION. The fast and deep molecular responses induced by
dasatinib compared with imatinib may be exploited to increase the proportion of patients who can achieve
a treatment-free remission after treatment discontinuation.
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Targeted therapy with tyrosine kinase inhibitors (TKIs) imati-
nib, dasatinib, nilotinib and bosutinib efﬁciently induces rapid
haematologic and cytogenetic responses in most newly diag-
nosed chronic-phase CML patients (1–7). In general, these
studies demonstrate that the second-generation TKIs
(2GTKIs) induce deeper and faster molecular and cytogenetic
responses than imatinib when given in ﬁrst line, but in spite of
this, there is no clear improvement in overall survival. 2GTKIs
prevent disease progression to advanced phase CML com-
pared with imatinib, although disease progression is rare with
any TKI. Side effects vary between these drugs. All have
varying degrees of haematological toxicity, of which nilotinib
and bosutinib have least and dasatinib most (1–7). Non-
haematological toxicity is generally different between these
drugs, and cross-intolerance is uncommon. Consequently,
patients with side effects have excellent alternatives. Of inter-
est, dasatinib treatment is associated with the appearance of
clonal NK and cytotoxic T lymphocytes in peripheral blood,
and this phenomenon is frequently accompanied by pleural or
pericardial effusions dominated by lymphocytes (8, 9).
Despite periods of discontinuations and dose reductions,
patients with these phenomena have very good treatment
responses compared with other patients, and it has been postu-
lated that the clonal lymphocytosis is part of an anti-leukaemic
immune response (10).
We conducted a randomised phase-2 trial (NordCML006) in
which the proportion of Philadelphia chromosome positive
leukaemic stem and progenitor cells (CD34+/CD38, and
CD34+/CD38+respectively) in bone marrow aspirates from 46
newly diagnosed patients with CML was analysed both at
diagnosis and during dasatinib and imatinib therapy (11).
Brieﬂy, at diagnosis, the proportion of leukaemic stem cells
varied markedly (1–100%) between individual patients but
correlated with leukocyte count, spleen size, haemoglobin and
blast percentage. A low leukaemic stem cell burden at diagno-
sis was associated with less therapy-related haematological
toxicity and superior cytogenetic and molecular responses dur-
ing the ﬁrst year of therapy. Of interest, and in contrast to in
vitro ﬁndings, TKI therapy very rapidly depleted most of leu-
kaemic stem cells in vivo (11). We here provide a detailed
report on the clinical data from this trial, with emphasis on
deep molecular responses and adverse events with a minimum
of 36 months of follow-up for all randomised patients.
Methods
Patients, randomisation and treatment
Newly diagnosed (not more than 3 months from diagnosis)
chronic-phase (CP) CML patients at least 18 yr of age were
eligible for the study. Pretreatment with hydroxyurea, but not
TKI, was allowed for up to 60 d. Hydroxyurea treatment was
given to 54% of included patients (mean 16 d in these 54%).
Mean time from the diagnosis of CML to start of TKI was
33 d. The study was performed in accordance with the Decla-
ration of Helsinki, and all patients provided written informed
consent. The study was approved by the relevant ethics review
boards and medicinal products agencies in Finland, Norway
and Sweden and registered at ClinicalTrials.gov
(NCT00852566). Imatinib was prescribed and reimbursed as
commercial drug, while dasatinib was provided as study drug
by Bristol-Myers Squibb. Patients were randomly assigned to
treatment groups (1 : 1), starting with standard dose of imati-
nib 400 mg QD (daily) or dasatinib 100 mg QD. In the case
of toxicity, two dose reduction steps were allowed: 70 and
50 mg for dasatinib and 300 and 200 mg for imatinib. In case
of insufﬁcient response, dose escalations were permitted, but
not above 140 mg QD of dasatinib or 400 mg twice daily
(BID) of imatinib. The primary endpoint of this study was the
proportion of Philadelphia chromosome-positive (Ph+)
CD34 + CD38 bone marrow cells after 6 months of treat-
ment as reported previously (11). Cytogenetic responses at 3,
6, 12 and 18 months and molecular responses at 1, 3, 6, 12
and 18 months were secondary endpoints and are reported
here. Later, an amendment to the protocol was made so that
patients were followed at yearly intervals from month 24 with
record of important medical events and response.
Procedures
Bone marrow (BM) samples for cytogenetic analysis were
taken at 0, 1, 3, 6, 12 and 18 months after therapy start.
Complete cytogenetic response (CCgR) was deﬁned as 0
Ph+ metaphases out of at least 20 analysed. BCR-ABL1 tran-
script levels were assessed by real-time quantitative PCR
(RQ-PCR) on peripheral blood samples at 0, 1, 3, 6, 12, 18,
24 and 36 months and performed in eight university molecu-
lar laboratories in Finland, Sweden and Norway. Results
were reported using the International Scale (IS) and accord-
ing to the ELN/EUTOS deﬁnitions (12, 13). One laboratory
was not standardised to IS (Tromsø, Norway, ﬁve patients
assessed), but this laboratory performed on par with others
in previous Nordic validation rounds of BCR-ABL1 RQ-PCR
and data were included in the analysis.
Statistical analysis
Two-sided tests for differences in distributions, repeated mea-
sures and correlations were performed with non-parametric
methods (Wilcoxon, Mann–Whitney, Fisher’s exact test, Krus-
kal–Wallis, Spearman’s rank tests), as appropriate. P-values
<0.05 were considered statistically signiﬁcant and calculated
using IBM SPSS Statistics version 18.0 (Armonk, NY, USA) .
All patients (n = 46) were followed for 36 months after
the start of the study drug. Unless speciﬁcally stated, all
analyses were performed by randomisation arm, that is,
according to the intention-to-treat principle (ITT). Missing
values were omitted from analysis.
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Results
Patient characteristics and treatments
Between March 2009 and October 2010 46 patients with
newly diagnosed CP-CML (24 women and 22 men) were
recruited at 10 academic centres in Finland (Helsinki), Nor-
way (Bergen, Oslo, Trondheim), and Sweden (Link€oping,
Lund, Stockholm, Umea and Uppsala). The mean age of the
patients was 56 yr (range 29–78 yr). Twenty-four patients
were randomly assigned to treatment with imatinib and 22
to dasatinib. Baseline characteristics by treatment group are
reported in Table 1. High-risk patients constituted 19 %
(Sokal), 9% (Euro/Hasford) and 15% (EUTOS) of the cohort.
Early cytogenetic and molecular responses
Early cytogenetic responses were superior in the dasatinib
arm as compared to the imatinib arm (Table 2). The median
percentage of Ph+ metaphases in the bone marrow at
1 month was 81% (imatinib) vs. 70% (dasatinib) and 5% vs.
0% at 3 months. At 3 months 82% of dasatinib treated, but
just 42 % of imatinib-treated patients were in CCgR
(Table 2).
The achievement of ≤10% BCR-ABL1 after 3 months of
therapy has recently been highlighted as an important mile-
stone (14). All but one of the dasatinib-treated patients
(95%), in contrast to 71% of those on imatinib, attained this
early goal of therapy (Fig. 1). At the same 3-month milestone,
more than one-third of dasatinib patients were already in
MR3.0 (previously denoted major molecular response or
MMR) but <10% of imatinib patients had reached this level
(Fig. 2A).
Cytogenetic and molecular responses from month 6
and onwards
Rates of CCgR were high at both 6 and 12 months
(Table 2). Missing data are due to insufﬁcient metaphases
for evaluation. At 6 months, all but two patients in each
treatment group had achieved this landmark, and at
12 months, all patients but one in the imatinib arm was in
CCgR.
MR3.0 (major molecular response) is a standard treatment
goal and regarded as a ‘safe haven’ in CML treatment.
Table 1 Patient characteristics
Dasatinib Imatinib
Number of patients 22 24
Female/Male 15/7 9/15
Mean age (range) in years 53 (29–71) 58 (38–78)
Sokal risk score median
(range)
LR/IR/HR
0.88 (0.61–4.20)
7/10/5
0.80 (0.57–13.22)
12/8/4
Euro risk score median
(range)
LR/IR/HR
912 (41–1839)
9/12/1
901 (182–2049)
7/14/3
EUTOS score median
(range)
LR/HR
55 (7–119)
19/3
33 (0–105)
20/4
LR/IR/HR is number of patients with low, intermediate and high risk,
respectively, for progression according to Sokal, Euro or EUTOS scor-
ing systems.
Table 2 Complete cytogenetic response (CCgR) during TKI therapy
Month
Rate of CCgR
Dasatinib Imatinib P-value
1 0/171 (0%) 0/24 (0%) 1
3 14/17 (82%) 8/18 (42%) 0.02
6 17/19 (89%) 15/17(88%) 0.91
12 20/20 (100%) 21/22 (95%) 0.33
1Number of patients with CCgR divided by number of evaluable sam-
ples (percentage).
TKI, Tyrosine kinase inhibitor.
Figure 1 Early molecular response. Percentage of patients achieving
≤10% BCR-ABL1 at 3 months in respective study arm.
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MR3.0 rates were superior for the dasatinib group as
compared to the imatinib group all through the ﬁrst year of
therapy (3, 6, 9 and 12 months) (Fig. 2A). The largest dif-
ference, 4-fold higher, was seen at 6 months (68% for dasat-
inib and 17% for imatinib). However, at later time points,
from 18 months and onwards, the MR3.0 rate was not signif-
icantly different between the two cohorts, as the imatinib-
treated patients caught up and both groups plateaued around
80%. With regard to deep molecular responses, MR4.0 and
MR4.5, a different pattern was seen. The fraction of patients
reaching MR4.0 was higher for dasatinib at all measured time
points throughout the study, (although not reaching statistical
signiﬁcance at 9 and 36 months) (Fig. 2B). Similarly, an
even deeper molecular response, MR4.5, was reached by sig-
niﬁcantly more dasatinib-treated patients at all time points
after 3 months (Fig. 2C). Of note, the poorest responder to
imatinib in the study was the patient who progressed to blast
phase. He was also the ﬁrst to attain MR4.5 in the imatinib
arm because of a successful stem cell transplant. Regardless
of this, the median level of BCR-ABL1 remained approxi-
mately 10-fold lower in the dasatinib arm than in the imati-
nib arm at each time point according to ITT analysis
(Table 3).
Progression and deaths
Three patients progressed on study, see also Fig. 3. One
patient developed blast phase after 2 months of imatinib
treatment (HR Sokal and an extra chromosome 19 at
diagnosis; still alive and in MR4.5 after allogeneic stem cell
transplantation). One patient on imatinib showed increased
Ph+ metaphases after 9 months from 1/25 to 4/25 and was
successfully switched to dasatinib. One patient on dasatinib
lost cytogenetic and molecular response after 9 months on
treatment. Subsequent mutation analysis of the BCR-ABL1
kinase domain showed the appearance of V299L, a mutation
which conveys resistance to dasatinib. The patient is pres-
ently alive treated with nilotinib, last BCR-ABL1 transcript
level 0.13% at month 36. One patient treated with imatinib
died from lung cancer diagnosed 9 months after diagnosis of
A
B
C
Figure 2 Molecular response. Percentage of patients reaching (A)
MR3.0, (B) MR4.0 and (C) MR4.5 on TKI therapy in respective study
arm at indicated time points. The number of evaluable patient sam-
ples per treatment arm and time point is given in Table 3.
Table 3 Median BCR-ABL1IS between study arms
Month
Median BCR-ABL1IS (%) (n = number
of evaluable samples)
PDasatinib Imatinib
1 16.6 (n = 21) 23.0 (n = 24) 0.38
3 0.22 (n = 22) 2.69 (n = 24) 0.011
6 0.06 (n = 22) 0.40 (n = 24) 0.011
9 0.020 (n = 22) 0.21 (n = 24) 0.005
12 0.007 (n = 21) 0.16 (n = 24) 0.009
18 <0.0032 (n = 22) 0.05 (n = 23) 0.048
24 <0.0032 (n = 22) 0.04 (n = 23) 0.035
36 <0.0032 (n = 21) 0.01 (n = 22) 0.09
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CML, and this was assessed as unrelated to CML and its
treatment.
Safety
Severe adverse events (mainly hospital admissions) occurred
in 13 dasatinib- and 10 imatinib-treated patients. These and
other adverse events are listed in Table 4. In terms of non-
haematological toxicity, six patients (27%) on dasatinib
developed pleural or pericardial effusions, frequently with
accompanying signs of inﬂammation. Imatinib treatment was
associated with more rash, hypophosphataemia (three
patients had grade 3) and gastrointestinal side effects. One
patient on imatinib had long-term elevated liver enzymes
and underwent a liver biopsy, which showed histological
signs of a suspected drug reaction with histopathological
resemblance to the ‘vanishing bile duct syndrome’. Liver
enzymes normalised after switch to dasatinib. Dasatinib, as
expected, induced more haematological toxicity than imatinib,
mostly short-term and grade 2. Dasatinib also suppressed two
or more cell lineages more frequently. Long-term cytopenias
were similar in both treatment groups, probably indicating
individual biological characteristics of the disease rather than
TKI toxicity.
Study drug discontinuation and dosing
Eight patients discontinued dasatinib and the reasons were
serosal effusions (ﬁve patients), progression (one patient)
and constitutional symptoms/lethargy (two patients) which
continued after change to another TKI. Discontinuation
because of serosal effusion was considered as drug-related;
the other three not. Seven patients discontinued imatinib,
and the reasons were blast phase (one patient), cytogenetic
progression (one patient), suboptimal response (less than
MR3.0 in two patients), rash (one patient), severe hypo-
gammaglobulinaemia with airway infections (one patient),
liver afﬂiction (one patient) and one patient with lung can-
cer. Hypogammaglobulinaemia, rash and liver afﬂiction were
considered imatinib-related, the others not. In Fig. 3, the
individual fates of patients are depicted up to 36 months.
The mean daily drug intake was calculated for the period,
the patient was on study drug including interruptions, but
not after discontinuation. During the ﬁrst 2 yr of treatment,
dasatinib patients on average received 92.7% of assigned
dose, that is, 92.7 mg daily, whereas imatinib patients
received 96.8% of assigned dose, that is, 387 mg daily.
During treatment year 3, the mean dose of dasatinib
decreased to 84.6 mg daily, but the dose of imatinib was
maintained at 388 mg daily. Dose reductions occurred in 6
dasatinib-treated patients, and at 3 yr, their mean dose was
50 mg daily. Compared with the eight patients who
remained on full-dose dasatinib throughout the study, these
6 dose-reduced patients did very well in terms of molecular
response (median MR4.5 in both groups, P = 0.53). Three
patients who discontinued imatinib switched to dasatinib and
also these patients performed well on low dose of dasatinib
(mean 63 mg OD). Also, when we combined all nine
patients on reduced dose of dasatinib to compare with the
eight patients on full-dose, we found no difference (both
groups attained median MR4.5 and P = 0.53).
Discussion
Large clinical trials with 2GTKIs have shown that dasatinib
and nilotinib induce more rapid and deeper responses in
Figure 3 Patient treatment course up to 36 months on study. Treatment at assigned or reduced dose is indicated in the major arrows. Patients
who discontinued study drug are shown as individual lines, and type of TKI therapy during the whole period is indicated. Reason for discontinua-
tion of study drug is given to the right of the individual patient lines. Stem cell transplant and death as indicated.
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newly diagnosed CP-CML patients as compared to imatinib
(4, 5). Despite this, no improvement of the excellent overall
survival of imatinib-treated patients has been observed with
2GTKIs, even though a small but signiﬁcant beneﬁt with
regard to progression to advanced phase is notable, at least
with nilotinib (2, 7). In many respects, data from the current
smaller study are in line with previous studies and even
appears to compare favourably with these. Furthermore,
dasatinib showed a clear beneﬁt over imatinib with respect
to depth of molecular response. As an example, at
12 months, MR3.0 rate was 80% with dasatinib compared to
45% with imatinib, and MR4.0 rates were 60% and 17%,
respectively. For both treatment arms, these numbers com-
pare favourably with data from DASISION, the dasatinib
registration study that was almost identically designed, but
also with data from Radich et al. (3, 5, 15). In DASISION,
the MR3.0 rate by 12 months was 46% for dasatinib and
28% for imatinib. In our study, a higher proportion of dasat-
inib patients achieved an even deeper molecular response,
MR4.5, compared with imatinib patients, at 24 months (52%
vs. 23%) and 36 months (61% vs. 21%). Again, comparing
with DASISION, the MR4.5 rates by 24 months were 17%
and 8% and after 36 months 22% vs. 12% (2, 7, 16).
There is no clear explanation to this difference between
our and previous studies of similar design. We applied a
strict ITT analysis with complete follow-up, which is a
strength of this study. ITT analysis also includes patients
who progressed or discontinued study drug and subsequently
received highly efﬁcacious rescue treatment by alternative
TKIs or allogeneic transplantation. In other studies, discon-
tinuation for whatever reason may be denoted as treatment
failure and excluded from further analysis. Also, classiﬁca-
tion of missing or inconclusive response assessments as ‘no
response’, may lead to falsely low estimates of response
rates compared to our study. The ITT approach provides a
clinician the best reﬂection of expected treatment course and
outcome in real life. We have also previously noted in our
imatinib+/-pegylated interferon-a2b study NordCML002,
that responses in Nordic patients treated both with imatinib
alone or the combination were superior to those in studies
with similar design (IRIS, French SPIRIT, CML-IV) (see
also supplementary table in ELN treatment recommendations
2013) (1, 17–20). In addition, in the recent update from
the Swedish population-based CML registry, very good
responses to TKI therapy were reported (21). Particular
characteristics of Nordic patients related to drug compliance
and/or genetic variation are possible explanations for
these results. The treatment groups in the current study were
representative of Nordic CML patients with an ordinary dis-
tribution of Sokal, Hasford and EUTOS risk scores. Notably,
Table 4 Adverse effects and discontinuation of study drug by 24 months classified by CTCAE 3.0
Severity
Dasatinib (n = 22) Imatinib (n = 24)
Grade 2 Grade 3-4 Grade 2 Grade 3-4
All non-haematological events 11 (50%) 7 (32%) 12 (50%) 12 (50%)
Progressive disease NA 1 (5%) NA 2 (4%)
Pleural effusion 3 (14%) 2 (9%) 0 (0%) 0 (0%)
Pericardial effusion 0 (0%) 1 (5%) 0 (0%) 0 (0%)
Unclear febrile conditions 3 (14%) 1 (5%) 0 (0%) 0 (0%)
Cholecystitis 0 (0%) 0 (0%) 0 (0%) 1 (4%)
Perianal abscess 0 (0%) 0 (0%) 0 (0%) 2 (8%)
Hypogammaglobulinaemia 0 (0%) 0 (0%) 0 (0%) 1 (4%)
Second cancer 0 (0%) 1 (5%) 0 (0%) 3 (13%)
Nausea/vomiting/dyspepsia 2 (9%) 0 (0%) 4 (17%) 1 (4%)
Cardiac infarction 0 (0%) 1 (5%) 0 (0%) 0 (0%)
Rash 2 (9%) 0 (0%) 4 (17%) 0 (0%)
Any haematological toxicity 10 (45%) 6 (27%) 4 (17%) 5 (22%)
Anaemia 10 (45%) 0 (0%) 3 (13%) 0 (0%)
Neutropenia 6 (27%) 3 (14%) 3 (13%) 5 (22%)
Thrombocytopenia 4 (18%) 3 (14%) 2 (9%) 1 (4%)
≥2-cell lineages affected NA 9 (41%) NA 5 (22%)
>6 months duration NA 5 (23%) NA 5 (22%)
Laboratory abnormalities
Liver enzymes 0 (0%) 1 (4%)
Hypophosphataemia 0 (0%) 3 (13%)
Discontinuation of study drug 7 (32%) 7 (29%)
The number (percentage) of patients with adverse events is shown. The list of grade 2 non-haematological events is not comprehensive but con-
sists of events judged as clinically relevant, for example, for duration or need of symptomatic treatment. Haematological toxicity was assessed in
all patients, except the patient with early blast crisis. The highest degree of toxicity is annotated.
NA, Not applicable.
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our patients with a mean age of 56 yr were clearly older
than patients in most published CML studies (in DASISION
patients were median 47 yr of age, i.e., 9 yr younger) and
thus also in this respect is more in accordance with the
everyday clinical setting.
Dasatinib was in the present study highly efﬁcacious
despite treatment interruptions, dosing reductions and a high
rate (27%) of serosal effusions. From earlier studies with
dasatinib, the occurrence of pleural effusions has been asso-
ciated with a better treatment response, and our data are in
line with this (10). In the current study, only 36 % of
patients randomised to dasatinib remained on full dose of
the drug after 36 months, while another 27% were on a
reduced dosing schedule mainly due to toxicity. However,
also patients that were dose-reduced exhibited deep molecu-
lar responses. In fact, when comparing the patients remaining
on full-dose dasatinib and those on reduced dose of the drug,
their molecular responses at 36 months were equally good
(median MR4.5 in both groups, P = 0.53). This supports other
retrospective reports where it has been suggested that
dasatinib at reduced or intermittent dosing improves tolerabil-
ity of the drug without loss of efﬁcacy (22–24). These
observations pose the question whether dasatinib at 100 mg
QD is the optimal dose for long-term use. A lower dose from
diagnosis of CP-CML or alternatively an induction phase with
standard dose followed by a lower maintenance dose which
might optimise the side effect proﬁle without compromising
efﬁcacy and also improve affordability of the drug.
Prospective studies to address this issue would be of interest.
In recent years, discontinuation of TKI therapy in CML
patients with very good therapeutic responses has become a
topic of high interest in academia and pharmaceutical indus-
try (25, 26). One example is the ongoing pan-European dis-
continuation study EURO-SKI, in which patients with stable
deep molecular responses (MR4.0 for at least 1 yr) can be
included. The treatment responses achieved primarily with
dasatinib in our study are promising in this respect. Our
results indicate that a substantial proportion of patients reach
minimal residual disease levels that may allow for a future
attempt to discontinue TKI therapy. Of note, 67 % of the
dasatinib-treated and 23% of imatinib-treated patients were
in MR4.0 at 3 yr and would be eligible for participation in
EURO-SKI. If discontinuation is the goal of treatment, our
data support the use of dasatinib rather than imatinib as ﬁrst
line therapy in newly diagnosed CML. Aiming for maximal
response is also supported by a recent report which showed
that achievement of MR4.5 on TKI therapy at 4 yr was asso-
ciated with a better survival at 8 yr as compared to lower
degrees of molecular response (27).
In summary, the treatment outcome in the current study
was very good in both treatment groups, both by cytogenetic
and by molecular evaluation, and the results compare
favourably with data from similarly designed larger trials.
The data give a realistic picture of the patient treatment
results as analysis is strictly on an intention-to-treat basis
and no patients were lost to follow-up. With respect to cyto-
genetic response and achievement of MR3.0, there was a
short-term beneﬁt of dasatinib, but imatinib patients caught
up with time. With respect to achievement of MR4.0 and
MR4.5, there was a clear advantage with dasatinib. In our
opinion, the optimal dose for long-term use of this potent
drug still is an open question, but dasatinib appears to have
an advantage if the treatment goal is to induce a deep
response. This may possibly inﬂuence long-term survival,
but more importantly may allow for a larger proportion of
patients to attempt discontinuation of TKI therapy and be
operationally cured. Future studies are needed to clarify
whether achieving a deep molecular response with potential
treatment-free survival should be a standard clinical treat-
ment goal in line with, for example, achievement of CCgR
and MR3.0. Issues such as quality of life, economy and tox-
icity will be important in this context.
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